CONTEXT: Graves' disease (GD) is a systemic autoimmune syndrome comprising manifestations in thyroid and orbital connective tissue. The link between these two tissues in GD eludes our understanding. Patients with GD have increased frequency of circulating monocyte lineage cells known as fibrocytes. These fibrocytes infiltrate orbital connective tissues in thyroid-associated ophthalmopathy and express functional TSH receptor (TSHR). OBJECTIVE: The aim of the study was to identify and characterize CD34(+) fibrocytes in thyroid tissue. DESIGN/SETTING/PARTICIPANTS: Patients undergoing surgical thyroidectomy at two academic medical centers were recruited to the study. MAIN OUTCOME MEASURES: We performed immunohistochemistry, flow cytometry, real-time PCR, cytokine-specific ELISA, and cell differentiation. RESULTS: CD34(+)ColI(+)CXCR4(+)TSHR(+) cells can be identified in situ in thyroid tissue from donors with GD, Hashimoto's thyroiditis, or in normal-appearing tissue. Thyroid fibroblasts cultivated from these glands express a CD34(-)ColI(+)CXCR4(+)TSHR(+) phenotype. TSHR levels are higher than those in orbital fibroblasts. When treated with TSH, thyroid fibroblasts generate IL-6 and IL-8. The induction of IL-6 can be blocked by dexamethasone, a chemical inhibitor of Akt/Pkb, and by knocking down Akt with a specific small interfering RNA. When treated with TGF-β or rosiglitazone, thyroid fibroblasts differentiate into myofibrocytes or adipocytes, respectively. CONCLUSIONS: ColI(+)CXCR4(+)TSHR(+) thyroid fibroblasts resemble orbital fibroblasts and circulating fibrocytes. CD34(+) fibrocytes appear to infiltrate both tissues in GD. Thyroid fibroblasts lose CD34 display in culture, unlike orbital fibroblasts and circulating fibrocytes. Fibrocytes and their fibroblast derivatives may participate in the pathogenesis of thyroid autoimmunity after TSHR activation. They could represent a therapeutic target for these diseases.
CONTEXT: Graves' disease (GD) is a systemic autoimmune syndrome comprising manifestations in thyroid and orbital connective tissue. The link between these two tissues in GD eludes our understanding. Patients with GD have increased frequency of circulating monocyte lineage cells known as fibrocytes. These fibrocytes infiltrate orbital connective tissues in thyroid-associated ophthalmopathy and express functional TSH receptor (TSHR). OBJECTIVE: The aim of the study was to identify and characterize CD34(+) fibrocytes in thyroid tissue. DESIGN/SETTING/PARTICIPANTS: Patients undergoing surgical thyroidectomy at two academic medical centers were recruited to the study. MAIN OUTCOME MEASURES: We performed immunohistochemistry, flow cytometry, real-time PCR, cytokine-specific ELISA, and cell differentiation. RESULTS:CD34(+)ColI(+)CXCR4(+)TSHR(+) cells can be identified in situ in thyroid tissue from donors with GD, Hashimoto's thyroiditis, or in normal-appearing tissue. Thyroid fibroblasts cultivated from these glands express a CD34(-)ColI(+)CXCR4(+)TSHR(+) phenotype. TSHR levels are higher than those in orbital fibroblasts. When treated with TSH, thyroid fibroblasts generate IL-6 and IL-8. The induction of IL-6 can be blocked by dexamethasone, a chemical inhibitor of Akt/Pkb, and by knocking down Akt with a specific small interfering RNA. When treated with TGF-β or rosiglitazone, thyroid fibroblasts differentiate into myofibrocytes or adipocytes, respectively. CONCLUSIONS: ColI(+)CXCR4(+)TSHR(+) thyroid fibroblasts resemble orbital fibroblasts and circulating fibrocytes. CD34(+) fibrocytes appear to infiltrate both tissues in GD. Thyroid fibroblasts lose CD34 display in culture, unlike orbital fibroblasts and circulating fibrocytes. Fibrocytes and their fibroblast derivatives may participate in the pathogenesis of thyroid autoimmunity after TSHR activation. They could represent a therapeutic target for these diseases.
Authors: Andrew G Gianoukakis; Timothy A Jennings; Chris S King; Christine E Sheehan; Neil Hoa; Paraskevi Heldin; Terry J Smith Journal: Endocrinology Date: 2006-10-26 Impact factor: 4.736
Authors: Roderick J Phillips; Marie D Burdick; Kurt Hong; Marin A Lutz; Lynne A Murray; Ying Ying Xue; John A Belperio; Michael P Keane; Robert M Strieter Journal: J Clin Invest Date: 2004-08 Impact factor: 14.808
Authors: Raymond S Douglas; Nikoo F Afifiyan; Catherine J Hwang; Kelvin Chong; Uzma Haider; Patrick Richards; Andrew G Gianoukakis; Terry J Smith Journal: J Clin Endocrinol Metab Date: 2009-11-06 Impact factor: 5.958
Authors: Erin F Gillespie; Konstantinos I Papageorgiou; Roshini Fernando; Nupur Raychaudhuri; Kimberly P Cockerham; Laya K Charara; Allan C P Goncalves; Shuang-Xia Zhao; Anna Ginter; Ying Lu; Terry J Smith; Raymond S Douglas Journal: J Clin Endocrinol Metab Date: 2012-03-07 Impact factor: 5.958
Authors: Collynn F Woeller; Elisa Roztocil; Christine L Hammond; Steven E Feldon; Richard P Phipps Journal: Am J Pathol Date: 2016-11-11 Impact factor: 4.307
Authors: Roshini Fernando; Ekaterina Placzek; Edmund A Reese; Andrew T Placzek; Samantha Schwartz; Aaron Trierweiler; Leslie M Niziol; Nupur Raychaudhuri; Stephen Atkins; Thomas S Scanlan; Terry J Smith Journal: J Clin Endocrinol Metab Date: 2017-03-01 Impact factor: 5.958
Authors: Erin F Gillespie; Nupur Raychaudhuri; Konstantinos I Papageorgiou; Stephen J Atkins; Ying Lu; Laya K Charara; Tünde Mester; Terry J Smith; Raymond S Douglas Journal: Invest Ophthalmol Vis Sci Date: 2012-11-21 Impact factor: 4.799
Authors: Roshini Fernando; Andrew Vonberg; Stephen J Atkins; Susan Pietropaolo; Massimo Pietropaolo; Terry J Smith Journal: J Clin Endocrinol Metab Date: 2014-02-11 Impact factor: 5.958